US 11,926,669 B2
Anti-FcRn antibody or antigen binding fragment thereof with improved stability
William Louis Macias, Indianapolis, IN (US); Su Liang, Briarcliff Manor, NY (US); Hyeakyung Ahn, Gyeonggi-do (KR); Haeyoung Yong, Gyeonggi-do (KR); Mijin Jung, Gyeonggi-do (KR); Minho Yoon, Gyeonggi-do (KR); Eunsun Kim, Seoul (KR); Seungkook Park, Seoul (KR); and Hyeeun Shim, Seoul (KR)
Assigned to HANALL BIOPHARMA CO., LTD., Daejeon (KR); and IMMUNOVANT SCIENCES GMBH, Basel (CH)
Filed by HANALL BIOPHARMA CO., LTD., Daejeon (KR); and Immunovant Sciences GmbH, Basel (CH)
Filed on Jun. 23, 2023, as Appl. No. 18/340,722.
Application 18/340,722 is a continuation of application No. PCT/US2023/067539, filed on May 26, 2023.
Claims priority of provisional application 63/499,116, filed on Apr. 28, 2023.
Claims priority of provisional application 63/377,283, filed on Sep. 27, 2022.
Claims priority of provisional application 63/370,772, filed on Aug. 8, 2022.
Claims priority of provisional application 63/352,948, filed on Jun. 16, 2022.
Prior Publication US 2023/0391876 A1, Dec. 7, 2023
Int. Cl. C07K 16/00 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/283 (2013.01) [A61P 37/06 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An anti-FcRn antibody or an antigen binding fragment thereof comprising:
a light chain variable region comprising LCDR1 comprising the amino acid sequence of SEQ ID NO: 9, LCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 3; and
a heavy chain variable region comprising HCDR1 comprising the amino acid sequence of SEQ ID NO: 11, HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 7.